Survivorship Programs Improve Quality of Life, Satisfaction in Prostate Cancer
the Cancer Therapy Advisor take:
Men with prostate cancer managed in a survivorship program report higher quality of life (QOL) and satisfaction than those who were managed by routine care, according to an article published online in Cancer.
In this study, patient-reported outcomes (PROs) such as QOL were integrated into a prostate cancer survivorship clinic and evaluated at 6 and 12 months.
Participants included 235 men being surgically treated for prostate cancer using routine follow-up care and 102 men managed in the survivorship clinic with the integrated point-of-care QOL reporting after radical prostatectomy.
Results showed that baseline QOL was comparable, but men in the survivorship groups had higher scores at 6 and 12 months than those following the routine care. For example, male patients in the survivorship clinic reported higher sexual function than those in routine care (52.2 vs 33.6 at 1 year, P<0.05).
The study suggests that disease-specific survivorship clinics with integrated QOL reporting may generate better results than clinics with routine care following cancer therapy.
Men with prostate cancer managed in a survivorship program report higher quality of life and satisfaction.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer